Pentadeca Arginate

Pentadeca Arginate (PDA) is not a new molecule — it is the arginine-salt form of BPC-157, carrying the identical 15-amino-acid sequence (GEPPPGKPADDAGLV, "pentadeca" = 15). The only difference from standard BPC-157 is the counterion: an arginine salt in place of the more common acetate. The peptide itself is unchanged. It is researched, like BPC-157, for tissue repair and cytoprotection, is not approved by the FDA or any regulator, and is supplied strictly for research use only.

What is Pentadeca Arginate, and how is it different from BPC-157?

PDA and BPC-157 are the same peptide sequence — the "arginate" refers only to the salt counterion paired with the molecule, not a change to the amino acids. Research-grade peptides are supplied as salts (a counterion improves stability or handling); BPC-157 is conventionally an acetate salt, and PDA is the same peptide as an arginine salt. Vendor materials claim the arginate form is dramatically more stable (e.g. "1,000× more stable" at stomach pH), but that claim has not been published in any peer-reviewed journal and appears to originate from compounding-vendor documentation, not independent testing. Treat the stability advantage as a marketing claim, not an established fact.

What does the research on PDA actually show?

There is no peer-reviewed study of pentadeca arginate as a distinct molecule — the entire evidence base belongs to BPC-157, and even that is almost entirely preclinical. BPC-157 has extensive rodent data for tendon, muscle, ligament, gut, and vascular healing (angiogenesis, collagen synthesis, anti-inflammatory effects), but a 2025 orthopaedic systematic review screened 544 records and identified only a single clinical study of BPC-157 — an uncontrolled retrospective knee-pain injection series in which 12 patients received BPC-157 alone. PDA itself has no clinical study of any kind. Evidence level: Preclinical (BPC-157, rodent); none specific to PDA. For full mechanism and evidence, see the BPC-157 profile.

Sources: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, Vasireddi N. et al., HSS J, 2025; Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain, Lee E., Padgett B., Alternative Therapies in Health and Medicine, 2021

Is PDA more effective than regular BPC-157?

No study has demonstrated that the arginate salt outperforms the acetate form in any biological outcome. Because the active peptide is identical, any difference would come only from pharmacokinetics (absorption/stability), and that has not been shown in independent, peer-reviewed research. Marketing that presents PDA as a clinically superior "next-generation BPC-157" is running ahead of the evidence.

What are the known side effects and safety concerns?

Because PDA is molecularly BPC-157, its safety picture is BPC-157's — a favorable preclinical profile with few reported adverse effects, but no comprehensive human safety data. BPC-157 — and therefore PDA, which is the same peptide — is prohibited by WADA at all times under S0 (non-approved substances) as of August 2026; it is not a compound an athlete in tested sport can use. There are no controlled human safety trials establishing a safe dose, and the arginate counterion has not been separately safety-characterized. Evidence level: Preclinical. See the legal status by country guide.

Source: WADA Prohibited List (current year)

Why does vendor verification matter for PDA?

Because "PDA" and "BPC-157" are the same peptide, a key verification question is simply whether a vial contains the correct pentadecapeptide at the labeled amount — and whether "arginate" branding is being used to justify a price premium over ordinary BPC-157. Independent HPLC (purity) and mass-spec (identity, free-peptide molecular weight ≈ 1,419.5 Da (the BPC-157 free base; the arginate is that same peptide supplied as an arginine salt)) are the objective checks. Learn how to read them in the how-to-test hub and the COA red-flags guide.

Source: BPC-157 (Body Protection Compound-157) — compound identity, PubChem (NCBI), PubChem, 2026

How does Peptigrity verify PDA vendors?

Peptigrity collects independent third-party Certificates of Analysis for PDA from shops' official channels and verifies each for authenticity before publishing. No COAs and no offers are on file for PDA yet — reflected in the 0 tests and 0 shops above — so there is currently nothing published to verify; that will change as the market for it develops. Because shops choose which COAs to publish, results reflect the batches shops make public rather than every batch, a selection bias we state openly, and a community-funded Testing Grant to buy and test vials anonymously is in development. When tests do appear they come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. A Certificate of Analysis can confirm what PDA is — the BPC-157 peptide sequence, its mass by mass spectrometry, and its HPLC purity. It cannot confirm the marketing around it: no COA can show that an "arginate salt" is more stable or more effective than the acetate, because those claims have never been tested in published research. Identity and purity are provable; the superiority story is not. The table above shows the cross-shop dataset. Our trust score weights independent lab purity and community reviews equally (50/50) — see how we calculate trust scores.

Educational information only; not medical advice. Pentadeca Arginate / BPC-157 is not approved by the FDA or any regulator for human use. Consult a qualified healthcare provider before using any research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend products or vendors.

Frequently asked questions